Literature DB >> 30323977

Elevated tumor tissue protein expression levels of kallikrein-related peptidases KLK10 and KLK11 are associated with a better prognosis in advanced high-grade serous ovarian cancer patients.

Xiaocong Geng1, Yueyang Liu1, Tobias Dreyer1, Holger Bronger1, Enken Drecoll2, Viktor Magdolen1, Julia Dorn1.   

Abstract

Several members of the KLK family have been proposed to modulate various tumor-relevant processes. Previously, we have shown that in advanced high-grade serous ovarian cancer tissue high KLK11 mRNA levels were significantly associated with prolonged overall and progression-free patients' survival. Furthermore, KLK11 mRNA expression positively correlated with KLK10 mRNA. In the present study, we examined the prognostic value for both KLK10 and KLK11 on the protein expression level by immunohistochemistry (IHC). A cohort encompassing 159 patient tumor samples afflicted with advanced high-grade (FIGO III/IV) serous ovarian cancer, present on tissue microarrays (TMA), was analyzed. For estimation of KLK10 and KLK11 immunoreactivity, an automated digital IHC image analysis algorithm was selected to quantify the antibody staining intensity in the tissues via an immunoreactive score (IRS). In line with the results obtained by mRNA analysis, KLK10 protein expression values were significantly and positively correlated with KLK11 protein expression values. In Kaplan-Meier analyses, both elevated KLK10, KLK11, and the combination of KLK10 and KLK11 protein levels were significantly linked with prolonged overall survival (OS). The addition of KLK10, KLK11 or the KLK10+KLK11 combination IRS to the base model in multivariate Cox analysis demonstrated that high KLK11 and KLK10+KLK11 protein expression levels, apart from clinical parameters, remained favorable independent predictive markers for OS. In conclusion, in the present study, we have validated the coordinate expression of KLK10 and KLK11 in advanced high-grade serous ovarian cancer. Furthermore, both increased KLK10 and KLK11 protein expression is associated with favorable prognosis in this major ovarian cancer subtype. The combined KLK10+KLK11 marker performed even stronger than KLK10 or KLK11 alone.

Entities:  

Keywords:  KLK10; KLK11; Kallikrein related peptidases; immunohistochemistry; ovarian cancer

Year:  2018        PMID: 30323977      PMCID: PMC6176182     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  30 in total

1.  Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.

Authors:  Martin W McIntosh; Yan Liu; Charles Drescher; Nicole Urban; Eleftherios P Diamandis
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

2.  Proteomics. Tissue-based map of the human proteome.

Authors:  Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén
Journal:  Science       Date:  2015-01-23       Impact factor: 47.728

3.  Diagnostic and prognostic significance of human kallikrein 11 (KLK11) mRNA expression levels in patients with laryngeal cancer.

Authors:  Christos Patsis; Ioannis Yiotakis; Andreas Scorilas
Journal:  Clin Biochem       Date:  2012-03-11       Impact factor: 3.281

4.  Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues.

Authors:  Chris Planque; Mireille Aïnciburu; Nathalie Heuzé-Vourc'h; Sandra Régina; Michèle de Monte; Yves Courty
Journal:  Biol Chem       Date:  2006-06       Impact factor: 3.915

5.  Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients.

Authors:  Lina Seiz; Julia Dorn; Matthias Kotzsch; Axel Walch; Nicolai I Grebenchtchikov; Apostolos Gkazepis; Barbara Schmalfeldt; Marion Kiechle; Jane Bayani; Eleftherios P Diamandis; Rupert Langer; Fred C G J Sweep; Manfred Schmitt; Viktor Magdolen
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

Review 6.  Human tissue kallikreins and testicular cancer.

Authors:  Liu-Ying Luo; George Yousef; Eleftherios P Diamandis
Journal:  APMIS       Date:  2003-01       Impact factor: 3.205

Review 7.  Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.

Authors:  Julia Dorn; Nathalie Beaufort; Manfred Schmitt; Eleftherios P Diamandis; Peter Goettig; Viktor Magdolen
Journal:  Crit Rev Clin Lab Sci       Date:  2014-02-03       Impact factor: 6.250

8.  Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus.

Authors:  Mitchell G Lawrence; John Lai; Judith A Clements
Journal:  Endocr Rev       Date:  2010-01-26       Impact factor: 19.871

9.  Kallikrein gene downregulation in breast cancer.

Authors:  G M Yousef; G M Yacoub; M-E Polymeris; C Popalis; A Soosaipillai; E P Diamandis
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

10.  IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples.

Authors:  Frency Varghese; Amirali B Bukhari; Renu Malhotra; Abhijit De
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

View more
  6 in total

1.  Loss of BRMS2 induces cell growth inhibition and translation capacity reduction in colorectal cancer cells.

Authors:  Yaofu Liu; Weimin Xu; Xin Xu; Zhengzhi Tan; Jing Xu; Lei Ma; Peng Du; Yili Yang
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

2.  Prospective quantitative gene expression analysis of kallikrein-related peptidase KLK10 as a diagnostic biomarker for childhood acute lymphoblastic leukemia.

Authors:  Shwan Majid Ahmad; Basima Sadq Ahmed; Karzan Ghafur Khidhir; Heshu Sulaiman Rahman
Journal:  PeerJ       Date:  2022-05-31       Impact factor: 3.061

3.  KLK11 acts as a tumor-inhibitor in laryngeal squamous cell carcinoma through the inactivation of Akt/Wnt/β-catenin signaling.

Authors:  Ruimin Zhao; Shiyang Wang; Junsong Liu; Chongwen Xu; Shaoqiang Zhang; Yuan Shao; Xiaoyi Duan
Journal:  J Bioenerg Biomembr       Date:  2021-01-09       Impact factor: 2.945

4.  Knockdown of KLK12 inhibits viability and induces apoptosis in human colorectal cancer HT-29 cell line.

Authors:  Qianyuan Li; Xiukou Zhou; Zhengyu Fang; Huamiao Zhou
Journal:  Int J Mol Med       Date:  2019-08-30       Impact factor: 4.101

5.  Systemic characterization of alternative splicing related to prognosis, immune infiltration, and drug sensitivity analysis in ovarian cancer.

Authors:  Qingyang Liu; Hao Zhang; Xiaocheng Yang; Xuesong Liu; Fanxing Yin; Panpan Guo; Yuhan Yin; Kaijiang Zheng; Zhuo Yang; Yanshuo Han
Journal:  Ann Transl Med       Date:  2022-01

6.  Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.

Authors:  Weiwei Gong; Yueyang Liu; Eleftherios P Diamandis; Marion Kiechle; Holger Bronger; Julia Dorn; Tobias Dreyer; Viktor Magdolen
Journal:  J Ovarian Res       Date:  2020-10-21       Impact factor: 4.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.